Placebo for valbenazine capsules
Sponsors
Neurocrine Biosciences Inc., Neurocrine Biosciences Inc., Neurocrine Biosciences Inc.
Conditions
Schizophrenia
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia
CompletedCTIS2022-502233-25-00
End: 2023-11-08Target: 199Updated: 2023-09-26
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia
CompletedCTIS2023-508433-14-00
Start: 2022-09-30End: 2025-02-11Target: 192Updated: 2024-10-14